OLMA
HealthcareOlema Pharmaceuticals, Inc. · Biotechnology · $1B
What is Olema Pharmaceuticals, Inc.?
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for women's cancers, headquartered in San Francisco, California.
Olema's primary focus is advancing OP-1250, an estrogen receptor antagonist and selective estrogen receptor degrader, through clinical trials for estrogen receptor-positive, HER2-negative breast cancer. The company does not yet generate product revenue and funds operations through capital markets activity while its lead candidate progresses through Phase 1/2 trials.
The company was incorporated in 2006 and is based in San Francisco, California.
- OP-1250 – lead clinical-stage ER antagonist and selective ER degrader
- Women's oncology pipeline targeting breast cancer
- Clinical-stage drug discovery and development platform
Is OLMA a Good Stock to Buy?
UQS Score rates OLMA as Poor overall, reflecting the early-stage nature of the business.
The Risk pillar stands out as the relative bright spot, suggesting the company's balance sheet and near-term financial structure are more stable than many peers at this stage.
Quality, Moat, and Growth all register as Weak, which is typical for pre-revenue clinical-stage biotechs with no approved products. Valuation is rated Elevated, meaning the current price may already reflect optimistic assumptions.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OLMA pay dividends?
No — Olema Pharmaceuticals, Inc. does not currently pay a dividend.
OLMA does not pay a dividend. As a clinical-stage company with no product revenue, capital is directed toward funding research, clinical trials, and pipeline development rather than shareholder distributions.
When does OLMA report earnings?
Olema Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue biotech, quarterly reports focus on clinical progress, cash runway, and operating expenses rather than sales or earnings growth. Investors typically watch pipeline milestones and trial readouts as the primary value drivers.
For the most recent quarter's results and clinical updates, visit Olema Pharmaceuticals' investor relations page.
OLMA Price History
-40.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Olema Pharmaceuticals, Inc.?
Based on Olema Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Olema Pharmaceuticals do?
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for women's cancers. Its lead candidate, OP-1250, targets estrogen receptor-positive, HER2-negative breast cancer and is currently in Phase 1/2 clinical trials.
Does OLMA pay dividends?
No, OLMA does not pay a dividend. The company is pre-revenue and reinvests all available capital into clinical development and research operations.
When does OLMA report earnings?
Olema Pharmaceuticals follows a standard quarterly reporting schedule. For exact dates and the latest financial disclosures, check the company's investor relations page directly.
Is OLMA a good stock to buy?
UQS Score rates OLMA as Poor overall. The Risk pillar is relatively stronger, but Quality, Moat, and Growth are all Weak, and Valuation is Elevated. The complete pillar analysis is available to Pro members.
Is OLMA overvalued?
UQS Score's Valuation pillar for OLMA is rated Elevated, suggesting the market price may already incorporate optimistic clinical outcomes. Clinical-stage biotechs often carry high valuation uncertainty ahead of trial results.
What is OLMA's market cap bracket?
OLMA is classified as a small-cap stock. Small-cap biotechs at the clinical stage typically carry higher risk and volatility than established large-cap pharmaceutical companies.
Is OLMA a long-term quality investment?
From a long-term quality perspective, UQS Score rates OLMA as Poor. The absence of revenue, a Weak Moat, and Elevated Valuation present meaningful hurdles. Long-term outcomes depend heavily on clinical trial success and eventual commercialization.
What sector does OLMA belong to?
OLMA operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on oncology, particularly therapies targeting women's cancers such as breast cancer.
Unlock Full OLMA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics and trend data
- ✓Compare OLMA against clinical-stage biotech peers
- ✓Get the full analyst-style quality report for Pro members
Pro Analysis
OLMA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 15.4 | 0.0 | 11.0 | 8.7 | 72.8 | 0.0 | -0.4 |
| Apr 2, 2026 | 15.8 | 0.0 | 11.0 | 10.8 | 72.8 | 0.0 | — |
OLMA — Pillar Breakdown
Quality
— 0.0/100 (25%)Olema Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 8.7/100 (20%)Olema Pharmaceuticals, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 72.8/100 (15%)Olema Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Olema Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Olema Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OLMA.
Score Composition
Financial Data
More Stock Analysis
How is the OLMA UQS Score Calculated?
The UQS (Unified Quality Score) for Olema Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Olema Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Olema Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.